Resources

News & Events
Details about upcoming launch of the European Patient Survey on CAR T-cell therapy
Next week, the T2EVOLVE and QUALITOP consortia will launch a survey developed to understand, analyze and meet the needs of European patients treated with CAR-T therapy for hematological cancers. To reach and engage as many patients as possible, T2EVOLVE's Work Package...
Happy holidays from everyone at T2EVOLVE
Join T2EVOLVE at the 5th European CAR T-cell meeting
The 5th European CAR T-cell Meeting takes place in Rotterdam, the Netherlands, on February 9-11, 2023. The meeting is the largest CAR-T event in Europe in 2023. The previous edition of the meeting had more than 1.000 on-site participants and 120 abstracts. For the...
Hélène Negre and Michael Hudecek to speak at Onco Cell Therapy Summit Europe
Hélène Negre, T2EVOLVE Project Leader, and Michael Hudecek, T2EVOLVE Project Coordinator, are speakers at the Onco Cell Therapy Summit Europe in Amsterdam on Thursday, November 3. Hélène will present the T2EVOLVE Consortium while Michael speaks about new targets and...
First face-to-face Strategic Consortium meeting takes place in Paris
The first face-to-face T2EVOLVE Strategic Consortium meeting took place in Paris over the course of two days last week. It was a pleasure for our work package team leads and contributors and T2EVOLVE coordinators to finally meet in person and work together. We hope to...
Spotlight sessions kick off
On September 19, the first T2E Spotlight Session kicked off with great success. Thanks to our speakers Juan Jose Lasarte (UNAV) and Maik Luu (UKW) for their insights into how to overcome the suppressive tumor microenvironment with new technologies and concepts and...

Latest Tweets

Publications
- Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations
- Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
- Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?
- CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models
- Targeting metabolic rewiring might decrease spread of tumor cells: Mitochondrial tRNA modifications promote cancer metastasis
- CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
- CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome

Materials
Partner perspectives
5th European CAR T-cell meeting posters
